State Demonopolization Committee said it received application from GlaxoSmithKline Export Limited on violation of competition legislation in medicinal products by Solvay Pharma. Both companies are producers of anti-flu vaccines. GlaxoSmithKline Export Limited produces vaccines under Fluarix, while Solvay Pharma manufactures vaccines under Influvac brand.

Solvay Pharma disseminated letter, which contains comparison of these two products and it said it is preferred to use Influvac.

Investigation showed that both vaccines are registered in Uzbekistan and allowed by the health authorities of Uzbekistan. Both vaccines protect people from flue in similar way.

The committee opened case against Solvay Pharma in line with the article 15 of Law “On advertisement” and article 8 of Law “On competition and limitation of monopoly activity in goods markets”. In particular, the committee underlined, the company incorrectly compared its own product with goods of other business entities.

The committee said Solvay Pharma violated advertisement and antimonopoly legislation of Uzbekistan and instructed to eliminate violations.